Amphastar Pharmaceuticals Inc(AMPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 14.73 | EPS (ttm) | 1.71 | Insider Own | 27.35% | Shs Outstand | 42.5M | Perf Week | -2.82% |
| Market Cap | 1.07B | Forward P/E | 7.93 | EPS next Y | 7.09% | Insider Trans | -0.29% | Shs Float | 30.9M | Perf Month | -4.3% |
| Enterprise Value | 1.47B | PEG | 6.89 | EPS next Q | 0.86 | Inst Own | 68.01% | Short Float | 14.25% | Perf Quarter | 31.07% |
| Income | 0.08B | P/S | 1.46 | EPS this Y | -8.88% | Inst Trans | -9.58% | Short Ratio | 9.49 | Perf Half Y | 17.42% |
| Sales | 0.73B | P/B | 1.39 | EPS next 5Y | 1.15% | ROA | 4.68% | Short Interest | 4.41M | Perf YTD | -6.12% |
| Book/sh | 18.06 | P/C | 3.66 | EPS past 3/5Y | 5.29% 134.65% | ROE | 10.3% | 52W High | -14.84% ($29.52) | Perf Year | 1.7% |
| Cash/sh | 6.88 | P/FCF | 6.99 | Sales past 3/5Y | 12.99% 15.53% | ROIC | 5.44% | 52W Low | 51.04% ($16.65) | Perf 3Y | -43.78% |
| Dividend Est. | - | EV/EBITDA | 8.19 | EPS Y/Y TTM | -38.09% | Gross Margin | 45.61% | Volatility(W/M) | 3.3% 3.55% | Perf 5Y | 31.01% |
| Dividend TTM | - | EV/Sales | 2.01 | Sales Y/Y TTM | 1.02% | Oper. Margin | 15.66% | ATR (14) | 0.9 | Perf 10Y | 35.23% |
| Dividend Ex-Date | - | Quick Ratio | 1.71 | EPS Q/Q | 6.44% | Profit Margin | 10.76% | RSI (14) | 47.47 | Recom | 3.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.4 | Sales Q/Q | 5.44% | SMA20 | -3.41% ($26.03) | Beta | 0.94 | Target Price | $22.5 |
| Payout | - | Debt/Eq | 0.9 | Earnings | 2026/8/6 | SMA50 | 3.65% ($24.25) | Rel Volume | 1.04 | Prev Close | $26.04 |
| Employees | 1976 | LT Debt/Eq | 0.88 | EPS/Sales Surpr. | 46.75% 2.21% | SMA200 | 12.76% ($22.3) | Avg Volume(3M) | 0.46M | Price | $25.14 |
| IPO | 2014/6/25 | Option/Short | Yes/Yes | Trades | 6533 | Volume | 483,151 | Change | -3.46% |
Ampastar Pharmaceutical Industries is a U.S. specialty and generic pharmaceutical company focused on injectable and inhaled products. It trades under the ticker AMPH. The company directly develops and manufactures products including the glucagon nasal powder BAQSIMI, the generic inhaler Primatene Mist, and injectable medications for emergency and chronic conditions such as epinephrine and lidocaine. Through a vertically integrated production system that spans from raw materials to finished products, it secures both quality and cost competitiveness at the same time.
Over the past 1 year, roughly in the middle
15% below its 1-year high.
Traded about as much as usual. That is 104% of its average volume.
AMPH makes money exceptionally well
Of every $100 in sales, $15.66 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -8.9% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $819. Peers typically go for $1,427. It is about in line with its own 5-year average.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +31.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 68.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #33 of 83 in the industry
Based on market cap of $1B.
PCRX#30 Pacira BioSciences Inc $1B PER 105.0 
ETON#31 Eton Pharmaceuticals Inc $1B PER 132.2 
CRON#32 Cronos Group Inc $1B PER 18.2 AMPH#33 Amphastar Pharmaceuticals Inc $1B PER 14.7 
HROW#34 Harrow Inc $1B PER - 
FAQ
What kind of company is AMPH?
AMPH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AMPH?
The market cap of AMPH is approximately $1.1B, ranking 2,530 within its sector.
What is the P/E ratio of AMPH?
AMPH has a P/E ratio of approximately 14.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AMPH?
AMPH has recorded a 52-week high of $29.52 and a low of $16.65.
